Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Revenue Recognized From Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three months ended March 31, 2015 and 2014:

	Three Months Ended March 31,
	2015		2014
Teva:
Recognition of upfront payment	$	2,876	$	3,025
Research funding		45		80
Genentech:
Recognition of upfront payment		179		786
Research funding		910		1,110
Total collaboration revenue	$	4,010	$	5,001